Filing Flows › Industrials › Bio Green Med Solution (BGMS)
Bio Green Med Solution (BGMS) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Bio Green Med Solution (BGMS) Q2 2026 earnings results →
Q2 2026 113¢ of every $1 of revenue lost · operating margin -117.1%
Bio Green Med Solution made $357K in Q2 2026. Operating margin -117.1%, net loss $405K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $357K in Q2 2026, down 52% from the previous quarter.
Operating costs exceeded revenue by $418K, an operating margin of -117.1%. The quarter ended with a net loss of $405K, wider than the previous quarter's $197K loss.
Operating cash flow was −$352K. Working capital and other items added $53K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $357K | — | -117.1% | −$405K | −$352K |
| Q1 2026 | 10-Q | May 15, 2026 | $743K | — | -33.1% | −$197K | −$278K |
| Q4 2025 | 10-K | Mar 30, 2026 | $666K | — | -162.5% | −$611K | −$33K |
| Q3 2025 | 10-Q | Nov 13, 2025 | $81K | +710% | n/m | −$988K | −$434K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Bio Green Med Solution
The following Business Section contains forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain risks, uncertainties and other factors including the risk factors set forth in Part I, Item 1A of this Annual Report on Form 10-K. In this report, “Bio Green Med Solution,” “BGMS,” the “Company,” “we,” “us,” and “our” refer to Bio Green Med Solution, Inc. ( fka Cyclacel Pharmaceuticals, Inc.). In December 2024, Bio Green Med Solution, Inc. (“BGMS” or the “Company”), a Delaware corporation formerly known as Cyclacel Pharmaceuticals, Inc., announced that it was in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company’s cash, including a potential transaction with investor, David E. Lazar of Activist Investing, LLC (“Lazar”).
In its own words, from its 10-K, filed Mar 30, 2026.
Bio Green Med Solution against its Wholesale-Durable Goods, NEC peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -117.1% against the peers' median -1.5%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BGMS Bio Green Med Solution | Q2 2026 | $357K | — | -117.1% |
| CNM Core & Main | Q2 FY27 | $2.1B | +2% | 10.6% |
| AENT Alliance Entertainment Holding | Q4 FY26 | $268M | +18% | -1.5% |
| GNLN Greenlane Holdings | Q2 2026 | $82K | -90% | n/m |
Source: Bio Green Med Solution 10-Q on SEC EDGAR · CIK 1130166 · Wholesale-Durable Goods, NEC
13F: who owns BGMS and who is buying
More on BGMS
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results